Free Trial
The Market Does Not Wait. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion
Thibault Boutherin

Thibault Boutherin Analyst Performance

Equity Research - Executive Director at Morgan Stanley

Thibault Boutherin is a stock analyst at Morgan Stanley in the medical sector, covering 2 publicly traded companies. Over the past year, Thibault Boutherin has issued 5 stock ratings, including buy, hold, and sell recommendations. While full access to Thibault Boutherin's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Thibault Boutherin's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
5 Last 0 Years
Buy Recommendations
25.00% 1 Buy Ratings
Companies Covered
2 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy25.0%1 ratings
Hold25.0%1 ratings
Sell50.0%2 ratings

Out of 4 total stock ratings issued by Thibault Boutherin at Morgan Stanley, the majority (50.0%) have been Sell recommendations, followed by 25.0% Buy and 25.0% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NYSE
50.0% of companies on NYSE
1 company
NASDAQ
50.0% of companies on NASDAQ
1 company

Thibault Boutherin, an analyst at Morgan Stanley, currently covers 2 companies listed on NYSE and NASDAQ, with the majority traded on NYSE.

Coverage Focus

Sector IconSectorPercentage
Medical
2 companies
100.0%

Thibault Boutherin of Morgan Stanley specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
LARGE CAP PHARMA
1 company
50.0%
MED - BIOMED/GENE
1 company
50.0%

Thibault Boutherin's Ratings History at Morgan Stanley

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
3/3/2026Upgrade$37.74$40.00Equal Weight
Alvotech stock logo
ALVO
Alvotech
12/3/2025Set Price Target$4.60$10.00
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
12/3/2025Reiterated Rating$47.47$42.00Underweight
Alvotech stock logo
ALVO
Alvotech
10/14/2025Set Price Target$7.97$14.00Overweight
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
9/29/2025Downgrade$55.61$47.00Underweight